Rebeca Cristina Oliveira Amorim

Rebeca Cristina Oliveira Amorim

Auto-generated profile, based on publicly available information

Rebeca Cristina Oliveira Amorim

Universidade Federal da Bahia, Brasil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PLPedro Henrique Melo Lima
Pedro Henrique Melo Lima
CLCaio Ferraz Lopes
Caio Ferraz Lopes
JFJoão Pedro Camargo Freire
João Pedro Camargo Freire
LFLucas Dias Feliciano
Lucas Dias Feliciano
RARebeca Cristina Oliveira Amorim
Rebeca Cristina Oliveira Amorim
FMFabrício De melo
Fabrício De melo
Acinetobacter baumannii is a gram-negative opportunistic pathogen associated with high morbidity and mortality in nosocomial infections, particularly in intensive care units. Multidrug resistance (MDR) is mediated by efflux pumps, lipopolysaccharide modifications, aminoglycoside adenylyltransferases, FosA, structural alterations, and production of enzymes that inactivate antibiotics, such as carbapenemases. These factors limit the therapeutic options and increase clinical challenges, as there are currently few drugs or combinations with therapeutic success against A. baumannii infections. Some strategies and new drugs, such as cefiderocol, eravacycline, sulbactam-darlobactam, tigecycline, and their combinations with colistin, are being tested and have shown apparent advances. This integrative review discusses the current resistance mechanisms and emerging therapeutic strategies aimed at overcoming the growing threat posed by MDR A. baumannii.